Nerandomilast: The lung function improved. The patient-reported outcomes did not.
Market Access Pharma
May 31, 2026
This week we finished a MARA Rating for a treatment for idiopathic pulmonary fibrosis — a progressive lung disease with limited options. The Phase 3 trial answered one question clearly: